JNJ-7706621は一種のパン-CDK阻害剤です。NJ-7706621はCDK1/2を抑制する作用が一番強くて、無細胞試験でIC50値が9 nM/4 nMになりますが、CDK1/2に作用する選択性はCDK3/4/6に作用する選択性より6倍以上がそれぞれ高くなって、オーロラA/Bにも有効に抑制することができますが、Plk1とWee1に抑制活性を表しません。

価格 在庫  
USD 151 あり
USD 264 あり
USD 296 あり
USD 466 あり
USD 1096 あり

JNJ-7706621 化学構造
分子量: 394.36





  • Compare CDK Inhibitors
  • 研究分野
  • JNJ-7706621のメカニズム



製品説明 JNJ-7706621は一種のパン-CDK阻害剤です。NJ-7706621はCDK1/2を抑制する作用が一番強くて、無細胞試験でIC50値が9 nM/4 nMになりますが、CDK1/2に作用する選択性はCDK3/4/6に作用する選択性より6倍以上がそれぞれ高くなって、オーロラA/Bにも有効に抑制することができますが、Plk1とWee1に抑制活性を表しません。
ターゲット CDK1/Cyclin B CDK2/Cyclin A CDK2/Cyclin E Aurora-A Aurora-B
IC50 9 nM 4 nM 3 nM 11 nM 15 nM [1]
In vitro試験 JNJ-7706621 also shows some inhibition to VEGF-R2, FGF-R2, and GSK3β, with IC50 of 154-254 nM. JNJ-7706621 shows inhibitory effect on a panel of human cancer cell types, including HeLa, HCT-116, SK-OV-3, PC3, DU145, A375, MDA-MB-231, MES-SA, and MES-SA/Dx5, with IC50 of 112-514 nM, independent of p53, retinoblastoma, or P-glycoprotein status. JNJ-7706621 is several-fold less potent at inhibiting growth of normal cell types, including MRC-5, HASMC, HUVEC, and HMVEC, with IC50 of 3.67-5.42 μM. In HeLa or U937 cells, JNJ-7706621 (0.5-3 μM) delays exit from G1, arrests cells in G2-M, induces endoreduplication, activates apoptosis, and reduces colony formation. [1] In a HeLa cell line, incremental treatment with increasing concentrations of JNJ-7706621 leads to a 16-fold resistance, which may be mediated by ABCG2. [2]
In vivo試験 In mouse xenograft model of A375 melanoma human tumor, JNJ-7706621 (100 or 125 mg/kg) causes tumor regression. [3]
特集 A broad-spectrum inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

In vitro kinase assay for CDK1 and Aurora kinases For CDK1 kinase activity, a method is developed using the CDK1/cyclin B complex purified from baculovirus to phosphorylate a biotinylated peptide substrate containing the consensus phosphorylation site for histone H1, which is phosphorylated in vivo by CDK1. Inhibition of CDK1 activity is measured by observing a reduced amount of 33P-γ-ATP incorporation into the immobilized substrate in streptavidin-coated 96-well scintillating microplates. CDK1 enzyme is diluted in 50 mM Tris-HCl (pH 8), 10 mM MgCl2, 0.1 mM Na3VO 4, 1 mM DTT, 1% DMSO, 0.25 μM peptide, 0.1 μCi per well 33P-γ-ATP, and 5 μM ATP in the presence or absence of various concentrations of JNJ-7706621 and incubated at 30 °C for 1 hour. The reaction is terminated by washing with PBS containing 100 mM EDTA and plates are counted in a scintillation counter. Linear regression analysis of the percent inhibition by JNJ-7706621 is used to determine IC50. The Aurora kinase assays are done with 10 μM ATP and a peptide containing a dual repeat of the kemptide phosphorylation motif.

細胞アッセイ: [3]

細胞株 HeLa, HCT-116, A375, SK-OV-3, MDA-MB-231, and PC-3 cells
濃度 1 nM - 10 μM, dissolved in DMSO
反応時間 48 hours
実験の流れ The ability of JNJ-7706621 to inhibit the proliferation of cell growth is determined by measuring incorporation of 14C-labelled thymidine into newly synthesized DNA within the cells. Cells are trypsinized and counted and 3-8 × 103 cells are added to each well of a 96-well CytoStar tissue culture treated scintillating microplate in complete medium in a volume of 100 μL. Cells are incubated for 24 hours in complete medium at 37 °C in an atmosphere containing 5% CO2. Next, 1 μL of JNJ-7706621 is added to the wells of the plate. Cells are incubated for 24 more hours. Methyl 14C-thymidine 56 mCi/mmol is diluted in complete medium and 0.2 μCi/well is added to each well of the CytoStar plate in a volume of 20 μL. The plate is incubated for 24 hours at 37 °C in JNJ-7706621 plus 14C-thymidine. The contents of the plate are discarded and the plate is washed twice with 200 μL PBS. 200 μL of PBS is added to each well. The top of the plate is sealed with a transparent plate sealer and a white plate backing sealer is applied to the bottom of the plate. The degree of methyl 14C-thymidine incorporation is quantified on a Packard Top Count.

動物実験: [1]

動物モデル Mouse xenograft model of A375 cells
製剤 Dissolved in 0.5% methylcellulose containing 0.1% polysorbate 80 in sterile water.
投薬量 100 or 125 mg/kg
投与方法 Orally or by intraperitoneal injection injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download JNJ-7706621 SDF
分子量 394.36


CAS No. 443797-96-4
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 79 mg/mL (200.32 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% methylcellulose+0.2% Tween 80 14 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名  4-​[[5-​amino-​1-​(2,​6-​difluorobenzoyl)​-​1H-​1,​2,​4-​triazol-​3-​yl]​amino]​-benzenesulfonamide

文献中の引用 (8)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related CDK 阻害剤

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanolは1種の有効的で、細胞浸透性の CDK 阻害剤で、cdc2-cyclin B、cdk2-cyclin A、cdk2-cyclin Eと cdk4-cyclin D1に対するIC50 値は4 nM、70 nM、35 nMと850 nMそれぞれに分かれます。

  • AT7519 HCl

    AT7519 HClは1種の多-CDK阻害剤で、CDK1/2/4/6/9に作用します。無細胞実験でそのIC50値は10~210 nMになります。AT7519 HClはCDK3に作用することは弱くて、CDK7に対して、ほとんど活性がありません。臨床2期。

  • Palbociclib (PD-0332991) HCl

    Palbociclib (PD-0332991) HClはCdksを抑制、Cdk4/ cyclin D1とCdk6/ cyclin D2に作用する時、IC50がそれぞれ11と16nMになる。

    Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionateは、非常に特定のCDK4CDK6の阻害剤で、 IC50 がそれぞれ11 nM と 16 nMです。

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib(SCH727965)は、小説と強力なサイクリン依存的なキナーゼ阻害剤で、 CDK2、 CDK5、 CDK1、 CDK9 に作用すると、 IC50 がそれぞれ 1 nM、1 nM、 3 nM 、4 nMになる。

  • Flavopiridol HCl

    Flavopiridol (Alvocidib) HClは、サイクリン依存的なkianses(CDK)を妨げるために、ATPと争いまして、 CDK1, CDK2, CDK4、CDK6 に作用すると、IC50が40 nMになり、CDK7に作用すると、IC50が 300 nMになる。

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib,CYC202)は有効な細胞週期卵白の依存性キナーゼ選択阻害剤、cdc2/ cyclin B、cdk2/ cyclin A、cdk2/ cyclin Eとcdk5/ p53に作用する時、IC50それぞれ0.65、0.7、0.7と0.16μM。

  • LY2835219

    LY2835219は CDK4CDK6 の強力かつ選択的な阻害剤で、IC50 がそれぞれ 2 nM と 10 nMです。


Tags: JNJ-7706621を買う | JNJ-7706621供給者 | JNJ-7706621を購入する | JNJ-7706621費用 | JNJ-7706621生産者 | オーダーJNJ-7706621 | JNJ-7706621代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID